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Abstract
Background & objectives: Malaria during pregnancy is a recognised risk factor for low birth weight
and probably decreases the survival of offspring, particularly during their first month of life. On the
other hand, acquired maternal immunity may protect infants against malaria infection or disease.
This study assesses these two opposite effects simultaneously.
Methods: We used the data of a large epidemiological study on malaria (Garki project) to analyse the
impact of malaria during pregnancy on survival of offspring in their first year of life. The dataset
contains 138,197 survey records, representing 12,849 subjects. Of 663 reported deliveries, 417 could
be linked to survival data for the newborn.
Results: The mortality rate during the first year of life was independent of maternal malaria infection
during pregnancy (crude rate ratio 1.0).  After adjustment for malaria in infancy, the rate ratio was
1.2. The corresponding rate ratios for maternal malaria during the second half of pregnancy were
1.46 and 1.73. None of these rate ratios was statistically significant.  This may be due to the small
number of deaths in the first year of life with a complete record of maternal malaria (27 deaths). The
infants during the first four months of life had the lowest risk for Plasmodium  falciparum, P. malariae
and P. ovale infections which may be partly due to acquired maternal immunity. There was a positive
association between malaria during pregnancy and malaria during first year of life which might be
due to similarity in exposure risks within a family, or confounding effects of socioeconomic status.
However, this association was weaker in the first four months of life, and in those women who
contracted infection during the second half of pregnancy.  This may indicate that acquired immunity
is stronger in this group and partially protects babies for a few months.
Interpretation & conclusion: It seems that on the whole, malaria during pregnancy was not a major
risk factor for infant mortality in the Garki project. These results suggest that ignoring acquired
maternal immunity may overestimate the hazard of malaria during pregnancy on infant survival.
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Introduction
Malaria during pregnancy, particularly close to term,
may entail two opposite effects on child survival. It may
protect the infant against malaria infection and severe
disease via acquired maternal immunity (AMI)1–5. Or it
may increase the risk of infant mortality, particularly
neonatal mortality, mostly by increasing the risk of low
birth weight, premature labour, intra-uterine growth
retardation, placental infection and stillbirth6–14.HAGHDOOST et al : MATERNAL MALARIA AND IMR 99
Few papers have quantified the impact of maternal
malaria on infant mortality (IM) directly based on the
survival of offspring in the first year of life6,11. These
studies mostly showed no significant association
between IM and maternal malaria. However, in a
review, Steketee et al7 suggested that 3–8% of infant
mortality (mortality during the first year of life) might
be due to maternal malaria in endemic areas. Some
authors have suggested that malaria accounts for even
more infant deaths than this12,13,15. None of these
predictions was directly derived from field data.
Most clinical trials assessed the efficacy of antimalaria
drugs during pregnancy by measuring their impacts on
low birth weight or neonatal mortality rate9, 11–19. These
studies mostly did not take account of the possible de-
creasing effect of antimalaria drugs on the AMI; there-
fore, they may overestimate the impact of malaria dur-
ing pregnancy on IMR. In this paper, we present one
of the few published analyses of the effect of malaria
infection during pregnancy on the first year survival
of offspring and assess the impact of AMI.
Material & Methods
The Garki project was carried out in a malaria-
endemic area of northern Nigeria from 1969–76 by
the World Health Organization (WHO) and an epide-
miology research team from the Government of Ni-
geria20. The anonomised Garki data are in the public
domain and the version used can be downloaded
from:http://www.sti.ch/en/research/biostatistics/
downloads.html.
The main objectives of the Garki project were to as-
sess malaria epidemiology, quantify the impact of
different interventions, and estimate required param-
eters for modelling of malaria transmission.   Data
were recorded at cross-sectional malariological sur-
veys of the entire population of the study villages,
during which malaria slides were prepared from all
individuals and recent deliveries and their outcomes
were recorded.  These surveys were administrated
every 10 weeks between 1970 and 73; some intervals
between 1974 and 76 were longer than 10 weeks. The
dataset contains 138,197 records, representing 12,849
subjects in 23 surveys in both interventions and non-
intervention arms. In our analysis, we included all
records of subjects in the non-intervention arm and
those records from intervention arms before and af-
ter the interventions (71,270 records).  We excluded
those data because interventions such as mass drug
administration might change the impact of malaria
during pregnancy on infant mortality rate.
Based on these data we constructed a cohort of infants
whose births were recorded retrospectively by inter-
viewing the mothers, and whose survival during the
first year of life was monitored at the cross-sectional
surveys. Originally, there was no direct link between
maternal and child records.  We created such a link
by matching on delivery date and residence of new
mothers.  If, in a neonate’s compound, there had been
only one delivery since the previous survey, then the
mother was inferred to be the woman who reported
that delivery.  Out of 663 reported deliveries, 417
were linked to neonates. Among them, 37 mothers
had twins and two had triplets recorded.  More than
96% of mothers had at least one blood slide in their first
half of pregnancy; the corresponding percent for the
second half of pregnancy was 91%.  Of the 458 live
births, 34 deaths were recorded before age of one year.
On average, infants were followed 232 days before
contracting malaria or death or reaching age one year.
Two approaches were used to analyse the data. In the
first approach, the age pattern of malaria infection risk
was assessed (in all selected records) to consider whether
the AMI could decrease the risk of infection in the first
few months of life.  A slide positive for malaria was used
as a proxy for AMI.  Logistic regression with random
effects was used to adjust odds ratios (ORs) for repeat-
ed observations on the same person.
In the second approach, the impact of malaria infec-
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sessed. Separate analyses were done for each half of
pregnancy and for pregnancy as a whole, using Cox
regression. For each analysis, women were included
if they had at least one slide result, and they were
classified as positive if at least one of the slides was
positive. These models were run in Stata version 8.0.
Maternal infection status is imperfectly observed in
this study, being based on slides made at intervals of
approximately 2–4 months, and with some mothers
having more slides than others.  To quantify the un-
certainity resulting from this variable sampling, we
fitted a Bayesian model by Markov Chain Monte
Carlo using WinBUGS version 1.3. The IMR was
defined as the number of deaths per year of follow-up
in the first year of life.  This differs from the common
definition, i.e. the number of deaths in first year of life
as a proportion of the number of births.
Results
The mean age, and the frequency of malaria infec-
tions among pregnant women in the three surveys
before delivery, did not differ significantly between
women whose pregnancies could be matched with a
baby and those whose could not (p = 0.41 and 0.58
respectively).
The mean and standard deviation of age of mothers
at the beginning of their pregnancies were 28.6 and
6.6 yr, respectively (minimum and maximum of 12.2
and 48.1 yr). Around 29.4% of pregnant women had
at least one positive slide for malaria [30% (112
slides) and 28.6% (109 slides) in the first and second
halves of pregnancy] and around 47% P. falciparum.
The frequency of P. falciparum infection in infants
(less than one year of age) was 53%, while the corre-
sponding frequencies for P. malariae and P. ovale
were 9 and 2%, respectively. Around 23.5% of
infant deaths were below the age of one month
(8 deaths), while only 1% of positive blood slides of
babies belonged to this age group. Overall, the risk
of malaria in those who died as infants was 30.2%,
while in the first year of life for those who reached age
one year, it was 8.8% (p = 0.009 by Fisher’s exact
test).
The risk ratios for maternal malaria infection in the
first and second halves of pregnancy for IMR were
0.74 and 1.46, respectively, but neither was statisti-
cally significant (Table 1). For maternal infection at
any time during pregnancy, taking into account the
varying number of slides by the Bayesian model,
produced a rate ratio for IMR of 1.05 with a wider
95% confidence interval (0.32–4.1).
Adjusting for the infant’s malaria infection increased
the rate ratios, more so for the second half of pregnan-
cy (crude RR = 1.46, adjusted RR = 1.73) than the
first.  In other words, having adjusted for a potential
protective effect of maternal acquired immunity,
malaria infection during pregnancy was a stronger
risk factor for IM.
Table 1. Infant mortality rates according to maternal malaria infection during pregnancy
Time of infection No. of deaths No. of deaths Rate ratio Adjusted rate
during pregnancy  in slide-negative in slide-positive (95% CI) ratio (95% CI)
group (person-years)   group (person-years)
First half 22 (169.1) 7 (79.9) 0.74 (0.31–1.72) 0.83 (0.36–1.96)
Second half 19 (188.1) 11 (74.2) 1.46 (0.7–3.07) 1.73 (0.8–3.58)
Any time 14 (125.12) 13 (123.89) 1.00 (0.47–2.14) 1.20 (0.56–2.56)
Due to their definitions, the numbers in last row is not the sum of the numbers in two first rows (see the last
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The population attributable fraction (PAF) for malaria
infection during pregnancy was – 0.01 (95%
CI: – 0.09 to 0.08). The corresponding PAF for the
second half of pregnancy was 0.12 (95% CI: – 0.16
to 0.33). The adjusted PAFs for infant malaria infec-
tion status were 0.06 (95% CI: – 0.034 to 0.34) and
0.16 (95% CI: – 0.11 to 0.36) respectively.
The frequency of P. falciparum infection in infants
was 53%, while the corresponding frequencies in
1–9 and 10 or more year old subjects were 86.5 and
35.4% respectively. These age-group specific fre-
quencies were 9, 33.4 and 7.8% for P. malariae, and
2, 4.2 and 1% for P. ovale correspondingly. These
frequencies show that the infection risks in the first
year of life were much less than the risks in 1–9 yr old
children (Table 2). In addition, the infection risks in
the first year of life had an increasing trend, i.e. these
frequencies were much lower in those aged less than
four months than those aged 8–12 months.
Table 2 also compares the age-specific infection fre-
quencies, taking those aged at least ten years as the
baseline group. Compared to the ORs in the 1–9 yr
age group, lower ORs in the first year of life might be
due to either less exposure to vectors, or partial pro-
tection via AMI abbreviation, or both.
To explore this issue more deeply, the ORs of infections
in the <4, 4–7 and 8–12 months of life were comput-
ed. The ORs for babies aged less than four months were
0.75, 0.56 and one for P. falciparum, P. malariae and
P. ovale, respectively which were much lower than the
ORs for the rest of first year of life (Table 2).
Malaria infections during pregnancy and infection
in their offspring showed a positive association
(OR=2.4, 95% CI: 1.48–3.88). This positive associ-
ation could be explained by the correlation between
exposure risk of mothers and infants; i.e. in highly
exposed families, both mothers and infants had higher
Table 2. The risk of infection with Plasmodium spp classified by age
Age group <4 months 4–7 months 8–12 months 1–9 year >10 year Total
No. (%) No. (%) No. (%) No. (%) No. (%)
P. falciparum
Negative 484 (70.7) 356 (42) 272 (31.6) 2,220 (13.5) 27,902 (64.6) 31,234
Positive 201 (29.3) 492 (58) 558 (68.4) 14,224 (86.5) 15,299 (35.4) 30,804
OR 0.75 2.52 3.9 11.68 1 χ2=1270*
(95% CI) (0.64–0.9) (2.2–2.9) (3.41–4.56) (11.13–12.27) – p <0.001
OR for the whole first year: 2.1 (1.8–2.4)
P. malariae
Negative 654 (95.9) 763 (90) 738 (85.8) 10,957 (66.6) 39,826 (92.2) 52,938
Positive 31 (4.5) 85 (10) 122 (14.2) 5,486 (33.4) 3,375 (7.8) 9,099
OR 0.56 1.31 1.95 5.9 1 χ2=6285*
(95% CI) (0.39–0.8) (1.04–1.65) (1.6–2.37) (5.63–6.2) – p <0.001
OR for the whole first year: 1.3 (1.1–1.5)
P. ovale
Negative 678 (99) 826 (97.4) 841 (97.8) 15,761 (95.8) 42,761(99) 60,867
Positive 7 (1) 22 (2.6) 19 (2.2) 682 (4.2) 440 (1) 1,170
OR 1 2.59 2.2 4.2 1 χ2=630*
(95% CI) (0.47–2.12) (1.68–4) (1.38–3.49) (3.72–4.75) – p <0.001
OR for the whole first year: 4.2 (3.6–5.0)
*Using χ2 test the associations between age group and the frequencies of each Plasmodium species were checked; the infection
risk in the last age group (>10 yr) is the baseline.102 J  VECT  BORNE  DIS  44, JUNE 2007
infection risks. However, this positive association
was weaker in infants with less than four months age;
and for those mothers who contracted infection in the
second half of their pregnancies (Table 3). These find-
ings were comparable for P. falciparum and P. malar-
iae infections and may imply that AMI generated
stronger protection in the first four months of infant
life, particularly in those pregnant women who con-
tracted infection in second half of pregnancy.
Discussion
We did not find evidence for a detrimental effect of
malaria in pregnancy on infant survival. The data are
consistent with a moderate to large risk, but the 95%
confidence interval for the rate ratio is wide even from
the model without allowing for variable number of
slides (0.44–2.0). The point estimate allowing for this
was similar, but had an even wider confidence inter-
val. On the whole, malaria infection during pregnancy
could account for around 6% of the IMR. Our anal-
ysis suggests that the effect of malaria infection on
offspring survival in the second half of pregnancy is
stronger than in the first half, which might be due to
its effect on birth-weight. In addition, infection dur-
ing pregnancy may produce partial immunity in in-
fants, particularly in their first four months life.
The short protective effect of AMI which observed
in this study is compatible with other published re-
sults2–5,21. Sehgal et al3 showed that maternal immu-
noglobulin G (IgG) was detectable in newborn babies
for around 4–7 months and its level had a negative as-
sociation with the risk of malaria infection.  Kitua et
al5 found that age profiles of malaria disease and of
the density of parasitaemia also complement those of
maternal IgG.  It seems that infants obtain partial
protection against malaria if the mother contracted
infection in late part of her pregnancy; but this pro-
tection is effective for only a few months.
There is a great deal of research on the hazards of
malaria during pregnancy on mothers and babies
health22. Most clinical trials have found that prophy-
laxis with antimalaria during pregnancy increased
birth weight and decreased the frequency of neona-
tal mortality9,11,13,16-19. Greenwood et al12 concluded
that maternal malaria prophylaxis could reduce IMR
by around 18% among the children of primigravidae,
and by around 4% among the children of multi-
Table 3. The odds ratios between maternal malaria infection during pregnancy
and infections in their off spring
Malaria during Malaria in infants
pregnancy
<4 months 4–8 months >8 months
P. falciparum
First half 2.8 (0.84–9.3) 2 (0.79–5.03) 1.78(0.8–3.98)
Second half 1.55(0.52–4.6) 3.1 (1.05–9.13) 2.1 (0.98–4.42)
Any time 1.58(0.6–4.1) 2.6 (1.12–6.1) 1.94(0.96–3.9)
P. malariae
First half – 0.31(0.03–3.2) 1.28(0.26–6.25)
Second half 0.84(0.16–4.55) 1.05(0.26–4.2) 1.93(0.57–6.6)
Any time 0.63(0.12–3.3) 0.73(0.23–2.37) 1.97(0.71–5.4)
Any species
First half 2.8 (0.86–9.2) 2.2 (0.87–5.52) 1.87(0.85–4.1)
Second half 1.43(0.5–4.1) 1.96(0.77–4.98) 2.2 (1.06–4.58)
Any time 1.63(0.59–4.52) 3.1 (1.23–7.81) 2.48(1.14–5.37)HAGHDOOST et al : MATERNAL MALARIA AND IMR 103
gravidae. However, this prediction was based on
the effect of prophylaxis on the birth weight and was
not adjusted for presumably protective effect of
AMI.
It is not clear whether low birth weight is on the causal
pathway between maternal malaria and infant mortal-
ity, and accurate prediction of the impact of malaria
control measures targeted at pregnant women re-
quires direct estimates of malaria attributable neona-
tal mortality rates22.  We estimate that malaria during
the whole pregnancy did not have any contribution on
IMR (PAF = – 0.01) which is compatible with the
results of studies which followed babies for one
year6,11. However, the adjusted PAF for maternal
immunity was 0.06, which may imply that without
allowing for AMI effect, malaria during pregnancy
slightly increased the IMR. The adjusted OR is close
to the prediction of Steketee et al7 (3–8%). Therefore,
the observed difference between studies might be due
to the impact of AMI.
It should be mentioned that our definition of IMR is
the number of deaths divided by the person months
of follow-up, which is different to its conventional
definition.  However, we do not expect this difference
had any impact on the final conclusion.
The crude and adjusted PAF of malaria during the
second half of pregnancy on IMR were 0.12 and 0.16
respectively, showing that malaria during the second
half of pregnancy is a stronger risk factor for IM.
Nonetheless, perhaps due to the low number of deaths
in first year of life, none of these PAFs was statisti-
cally significant.
It seems that even the large database from Garki is in-
adequate for accurately measuring the specific associ-
ation between malaria during pregnancy and IM. This
association was not a primary objective in the Garki
project; and the number of births that could be linked
to maternal malaria status was nevertheless small, so
the confidence limits for the estimates are wide.
Conclusion
Around 6% of IMR could be attributed to maternal
malaria during pregnancy. It seems that most previous
studies over-estimated the impact of malaria on surviv-
al of infants because they do not consider protective
effect of AMI. To demonstrate unequivocally an excess
risk of infant mortality would require a large longitu-
dinal study, which would also need to measure possi-
ble confounding factors such as socioeconomic status
and to take account of AMI.
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